Literature DB >> 17656106

Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors.

Matthew F Mescher1, Flavia E Popescu, Michael Gerner, Chris D Hammerbeck, Julie M Curtsinger.   

Abstract

Naïve CD8 T cells respond to signals provided by Ag, costimulation and cytokines by proliferating and differentiating to develop effector functions. Following initial clonal expansion, however, the cells develop activation-induced non-responsiveness (AINR), a form of anergy characterized by an inability to produce IL-2. Cells in the AINR state can carry out effector functions (cytolysis, IFN-gamma production) but cannot continue to proliferate and expand in the face of persisting Ag. AINR limits the ability of activated CTL to control tumor growth but can be reversed by IL-2, provided either therapeutically or by activated CD4 T helper cells, to allow continued expansion.

Entities:  

Mesh:

Year:  2007        PMID: 17656106      PMCID: PMC2693139          DOI: 10.1016/j.semcancer.2007.06.008

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  82 in total

1.  Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL response.

Authors:  Ee Loon Tham; Protul Shrikant; Matthew F Mescher
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

2.  The poststimulation program of CD4 versus CD8 T cells (death versus activation-induced nonresponsiveness).

Authors:  Ee Loon Tham; Matthew F Mescher
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

3.  IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion.

Authors:  Warren N D'Souza; Leo Lefrançois
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

4.  PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.

Authors:  LauraL Carter; Lynette A Fouser; Jason Jussif; Lori Fitz; Bija Deng; Clive R Wood; Mary Collins; Tasuku Honjo; Gordon J Freeman; Beatriz M Carreno
Journal:  Eur J Immunol       Date:  2002-03       Impact factor: 5.532

5.  Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis.

Authors:  Protul Shrikant; Matthew F Mescher
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

6.  PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.

Authors:  Yvette E Latchman; Spencer C Liang; Yin Wu; Tatyana Chernova; Raymond A Sobel; Martina Klemm; Vijay K Kuchroo; Gordon J Freeman; Arlene H Sharpe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

7.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.

Authors:  Christopher A Klebanoff; Steven E Finkelstein; Deborah R Surman; Michael K Lichtman; Luca Gattinoni; Marc R Theoret; Navrose Grewal; Paul J Spiess; Paul A Antony; Douglas C Palmer; Yutaka Tagaya; Steven A Rosenberg; Thomas A Waldmann; Nicholas P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-04       Impact factor: 11.205

Review 8.  CTLA-4: new insights into its biological function and use in tumor immunotherapy.

Authors:  Jackson G Egen; Michael S Kuhns; James P Allison
Journal:  Nat Immunol       Date:  2002-07       Impact factor: 25.606

9.  Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells.

Authors:  Susan M Kaech; Joyce T Tan; E John Wherry; Bogumila T Konieczny; Charles D Surh; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-11-16       Impact factor: 25.606

10.  The CD8 T cell response to vaccinia virus exhibits site-dependent heterogeneity of functional responses.

Authors:  Zhengguo Xiao; Julie M Curtsinger; Martin Prlic; Stephen C Jameson; Matthew F Mescher
Journal:  Int Immunol       Date:  2007-06-01       Impact factor: 4.823

View more
  22 in total

Review 1.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

2.  Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases.

Authors:  Shuko Murakami; Yasumitsu Nishimura; Megumi Maeda; Naoko Kumagai; Hiroaki Hayashi; Ying Chen; Masayasu Kusaka; Takumi Kishimoto; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2009-03-18       Impact factor: 3.674

Review 3.  Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey.

Authors:  Mohamed A ElTanbouly; Randolph J Noelle
Journal:  Nat Rev Immunol       Date:  2020-10-19       Impact factor: 53.106

Review 4.  Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance.

Authors:  Tijana Martinov; Brian T Fife
Journal:  Ann N Y Acad Sci       Date:  2019-04-26       Impact factor: 5.691

5.  Chronic alcohol consumption inhibits melanoma growth but decreases the survival of mice immunized with tumor cell lysate and boosted with α-galactosylceramide.

Authors:  Faya Zhang; Zhaohui Zhu; Gary G Meadows; Hui Zhang
Journal:  Int Immunopharmacol       Date:  2015-06-25       Impact factor: 4.932

Review 6.  Never say die: survival signaling in large granular lymphocyte leukemia.

Authors:  Mithun Vinod Shah; Ranran Zhang; Thomas P Loughran
Journal:  Clin Lymphoma Myeloma       Date:  2009

7.  Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma.

Authors:  Gautam Jha; Jeffrey S Miller; Julie M Curtsinger; Yan Zhang; Mathew F Mescher; Arkadiusz Z Dudek
Journal:  Am J Clin Oncol       Date:  2014-06       Impact factor: 2.339

8.  IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.

Authors:  Mary Zimmerman; Dafeng Yang; Xiaolin Hu; Feiyan Liu; Nagendra Singh; Darren Browning; Vadivel Ganapathy; Phillip Chandler; Divaker Choubey; Scott I Abrams; Kebin Liu
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

9.  The Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells.

Authors:  Sha Wu; Wei Zhu; Yibing Peng; Lan Wang; Yuan Hong; Lei Huang; Dayong Dong; Junping Xie; Todd Merchen; Edward Kruse; Zong Sheng Guo; David Bartlett; Ning Fu; Yukai He
Journal:  Cancer Immunol Res       Date:  2017-08-29       Impact factor: 11.151

10.  CD8+ T cell exhaustion, suppressed gamma interferon production, and delayed memory response induced by chronic Brucella melitensis infection.

Authors:  Marina Durward-Diioia; Jerome Harms; Mike Khan; Cherisse Hall; Judith A Smith; Gary A Splitter
Journal:  Infect Immun       Date:  2015-09-28       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.